The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s research includes a study on a targeted therapy combination for treating low-grade childhood glioma with a BRAF V600 mutation.
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include advances in treating HER2-low metastatic breast cancer, RAS wild-type metastatic colorectal cancer, recurrent and refractory Ewing sarcoma, and newly diagnosed multiple myeloma.
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include targeted therapy for advanced hormone receptor-positive, HER2-negative breast cancer and using liquid biopsy to guide post-surgery treatment decisions for stage II colon cancer.
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma.
In this month’s “From the Editor in Chief” column, Dr. Jyoti Patel discusses the return of the American Society of Clinical Oncology (ASCO) Annual Meeting in person and online, and why bringing oncology professionals, researchers, advocates, and people with cancer back together is so important for cancer care.
La Reunión Anual de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica) de 2022 se llevará a cabo del 3 al 7 de junio. En esta publicación inicial de la investigación que se presenta en la reunión, los estudios examinan cómo la raza, el origen étnico, la pobreza y otros factores sociales y demográficos afectan la vida de las personas con cáncer.
The 2022 ASCO Annual Meeting is being held June 3 to 7. In this early release of research being presented at the meeting, studies examine how race, ethnicity, poverty, and other social and demographic factors affect the lives of people with cancer.
Read research from the April 2022 session of the ASCO Plenary Series, which highlights a clinical trial that studied a medication called tislelizumab combined with chemotherapy to treat recurrent or metastatic nasopharyngeal cancer.
In this podcast, Dr. Kedar Kirtane discusses research from the 2022 Multidisciplinary Head and Neck Cancers Symposium, including discussions around cancer disparities in head and neck cancer, treatment for HPV-positive oropharyngeal cancer, and strategies for treating HPV-related head and neck cancers.
Read research from the March 2022 session of the ASCO Plenary Series, which highlights an immunotherapy combination to treat advanced melanoma and adding immunotherapy to chemotherapy to treat advanced non-small cell lung cancer.
